Want to see ALT full AI Analyst Report?
ALT Stock Chart & Stats
$3.50
$0.16(2.19%)
At close: 4:00 PM EST
$3.50
$0.16(2.19%)
Day’s Range― - ―
52-Week Range$2.56 - $6.44
Previous CloseN/A
Volume1.55M
Average Volume (3M)4.17M
Market Cap
$558.14M
Enterprise Value$87.61
Total Cash (Recent Filing)$331.54M
Total Debt (Recent Filing)$35.85M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding194,474,150
10 Day Avg. Volume3,291,859
30 Day Avg. Volume4,174,562
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.41
Price to Sales (P/S)7757.46
P/FCF Ratio-4.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.70Price Target Upside262.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$7.00K
Bulls Say, Bears Say
Bulls Say
Cash Runway / FinancingA pro forma cash position of roughly $535M materially reduces near-term financing risk and funds pivotal Phase III start-up, global site activation and 52-week endpoint operations. This financial cushion supports sustained program execution and gives management optionality over the next multi-year development cycle.
Regulatory RecognitionBreakthrough Therapy designation signals FDA recognition of potential substantial clinical benefit and typically enables closer agency interactions and potential expedited paths. That regulatory recognition raises the program's strategic value and can shorten development friction, benefiting long-term approval probability.
Late‑stage Development ReadinessFinalized global Phase III protocol with regulatory alignment and CRO engagement reduces execution uncertainty versus earlier-stage programs. Being positioned to commence a pivotal, registrational trial reflects de‑risking of clinical development and focuses resources on a single lead asset with a clear path to potential approval.
Bears Say
Sustained Cash BurnA recurring negative operating and free cash flow profile of about -$72M TTM means the company will continue to consume capital until commercialization or material revenue begins. Even with current cash, extended burn elevates the probability of future financing, diluting shareholders or constraining program scope long term.
No Commercial Revenue; Heavy LossesMinimal revenue and deeply negative net income indicate Altimmune remains pre‑commercial and dependent on external funding. Without recurring product sales, profitability is distant and operating leverage is limited; sustained losses pressure equity and force tradeoffs between clinical investment and cash preservation.
Competitive & Timeline RiskIntensifying GLP-1 and multi-agonist competition increases the need for clear differentiation on tolerability and liver targeting. Coupled with a long, 52‑week biopsy primary endpoint and few interim analyses, this extends commercialization risk and raises chances competitors reach market first or set higher efficacy benchmarks.
Altimmune News
ALT FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was $2.56 and its highest was $6.44 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is $558.14M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on May 13, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.062.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune pays a Monthly dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune dividends here
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.15.
How many shares outstanding does Altimmune have?
Altimmune has 194,474,150 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went down -1.948%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in ALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Altimmune Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.70 (262.86% Upside)
$12.70 (262.86% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
113.42%
Trailing 12-Months
Company Description
Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
ALT Stock 12 Month Forecast
Average Price Target
$12.70
▲(262.86% Upside)
Technical Analysis
Tvardi Therapeutics
―
Diamedica Therapeutics
―
Alpha Tau Medical Ltd
―
enGene Holdings
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.45% Insiders
9.34% Mutual Funds
0.42% Other Institutional Investors
74.51% Public Companies and
Individual Investors